Upgrade to SI Premium - Free Trial

Merck's (MRK) LYNPARZA Phase 3 SOLO3 Trial Demonstrated 72% OR Rate in Patients with Platinum-Sensitive Relapsed gBRCAm

June 3, 2019 4:19 PM
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada), today presented full results from the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles